Key facts
- SpyGlass Pharma (NAS: SGP)’s last known valuation is $510.6M (Feb 2026).
- It has raised $348.5M across 2 recorded rounds; the latest was Later Stage VC (Series D) ($75.0M) in Jun 2025.
- Notable investors include RA Capital Management, New Enterprise Associates, Sands Capital, Samsara BioCapital, Gilde Healthcare — 7 tracked in total.
- Status: Publicly Held.
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for SpyGlass Pharma (NAS: SGP)
Funding rounds
2 roundsAbout SpyGlass Pharma (NAS: SGP)
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.
- Industry
- Surgical Devices
- Sector
- Healthcare
- HQ
- Aliso Viejo, CA, United States
- Founded
- 2019
- Employees
- 65
- Website
- spyglasspharma.com/
- Ownership
- Publicly Held
SpyGlass Pharma (NAS: SGP) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SpyGlass Pharma (NAS: SGP) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SpyGlass Pharma (NAS: SGP) in its N-PORT filings yet. We sweep new filings monthly.